Treatment News : Quality of Life Improved Most in Women and African Americans After Switching HIV Treatment in the GRACE Study

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 13, 2011

Quality of Life Improved Most in Women and African Americans After Switching HIV Treatment in the GRACE Study

HIV treatment-experienced women and African Americans had greater improvements in quality of life than men, whites or Latinos after switching to a regimen that contained Prezista (darunavir). These new data from the GRACE study were presented at the 1st International Workshop on HIV and Women, held January 10 to 11 in Washington, DC, and reported by the National AIDS Treatment Advocacy Project (NATAP).

The purpose of the GRACE study was to determine whether the efficacy and safety of Prezista—in treatment-experienced patients—were equivalent across both gender and race. Unlike most antiretroviral (ARV) drug studies in the United States, more than two thirds of the GRACE participants were women and more than two thirds were black. Ultimately, GRACE found no significant differences based on gender, but black participants were less likely than white or Latino participants to maintain undetectable HIV levels over the course of the study—largely due to the fact, according to later analysis, that far fewer black participants were retained in the study.

Researchers in the GRACE study also conducted extensive questionnaires called the Functional Assessment of HIV Infection (FAHI), which is based on 47 questions concerning cognitive function and physical, emotional, functional and social well-being. FAHI scores range from a low of 0 to a high of 176. The current analysis focused on those measures.

The study’s authors reported that quality of life increased dramatically for all participants after switching to a new regimen containing Prezista, with 30 percent gains by week four of the study and 70 percent gains by week 48.

Before people started treatment there were no differences in FAHI scores based on either race or gender. Over time, however, scores increased by a significantly higher degree in women compared with men (80 percent compared with 60 percent), and in black participants compared with either Latino or white participants (90 percent compared with 50 percent for Latinos and whites).

Other factors that predicted greater gains in quality of life included having a lower CD4 count, a lower FAHI score or a higher viral load, all before switching treatment. Two other factors that predicted increased quality of life were a history of psychiatric disorders and a better virologic response to treatment.

The authors conclude that although women and black participants were more likely to drop out of the trial, and black participants were less likely than Latino or white participants to maintain good virologic control, it is heartening to know that switching treatment can bring greater gains in quality of life to these two groups.

Search: GRACE, race, gender, Prezista, darunavir, Workshop on HIV and Women, quality of life, FAHI


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.